|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PI4KB |
Gene summary for PI4KB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PI4KB | Gene ID | 5298 |
| Gene name | phosphatidylinositol 4-kinase beta | |
| Gene Alias | NPIK | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q9UBF8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5298 | PI4KB | LZE2T | Human | Esophagus | ESCC | 2.90e-02 | 3.99e-01 | 0.082 |
| 5298 | PI4KB | LZE4T | Human | Esophagus | ESCC | 7.43e-07 | 9.70e-02 | 0.0811 |
| 5298 | PI4KB | LZE7T | Human | Esophagus | ESCC | 8.68e-05 | 4.90e-01 | 0.0667 |
| 5298 | PI4KB | LZE8T | Human | Esophagus | ESCC | 1.01e-03 | 1.28e-01 | 0.067 |
| 5298 | PI4KB | LZE20T | Human | Esophagus | ESCC | 2.56e-06 | 1.24e-01 | 0.0662 |
| 5298 | PI4KB | LZE24T | Human | Esophagus | ESCC | 4.42e-12 | 3.63e-01 | 0.0596 |
| 5298 | PI4KB | P1T-E | Human | Esophagus | ESCC | 1.44e-09 | 4.98e-01 | 0.0875 |
| 5298 | PI4KB | P2T-E | Human | Esophagus | ESCC | 1.96e-36 | 4.83e-01 | 0.1177 |
| 5298 | PI4KB | P4T-E | Human | Esophagus | ESCC | 2.36e-12 | 1.51e-01 | 0.1323 |
| 5298 | PI4KB | P5T-E | Human | Esophagus | ESCC | 2.58e-14 | 1.72e-01 | 0.1327 |
| 5298 | PI4KB | P8T-E | Human | Esophagus | ESCC | 1.20e-22 | 2.65e-01 | 0.0889 |
| 5298 | PI4KB | P9T-E | Human | Esophagus | ESCC | 1.86e-09 | 3.31e-01 | 0.1131 |
| 5298 | PI4KB | P10T-E | Human | Esophagus | ESCC | 1.16e-16 | 3.93e-01 | 0.116 |
| 5298 | PI4KB | P11T-E | Human | Esophagus | ESCC | 1.49e-19 | 5.80e-01 | 0.1426 |
| 5298 | PI4KB | P12T-E | Human | Esophagus | ESCC | 2.94e-18 | 1.99e-01 | 0.1122 |
| 5298 | PI4KB | P15T-E | Human | Esophagus | ESCC | 3.89e-20 | 5.46e-01 | 0.1149 |
| 5298 | PI4KB | P16T-E | Human | Esophagus | ESCC | 1.28e-19 | 3.24e-01 | 0.1153 |
| 5298 | PI4KB | P17T-E | Human | Esophagus | ESCC | 1.43e-09 | 4.44e-01 | 0.1278 |
| 5298 | PI4KB | P19T-E | Human | Esophagus | ESCC | 4.38e-06 | 6.06e-01 | 0.1662 |
| 5298 | PI4KB | P20T-E | Human | Esophagus | ESCC | 5.45e-17 | 3.43e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
| GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
| GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
| GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
| GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
| GO:000689818 | Esophagus | ESCC | receptor-mediated endocytosis | 142/8552 | 244/18723 | 5.22e-05 | 4.05e-04 | 142 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:00066611 | Esophagus | ESCC | phosphatidylinositol biosynthetic process | 73/8552 | 131/18723 | 1.31e-02 | 4.28e-02 | 73 |
| GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
| GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
| GO:0006661 | Liver | HCC | phosphatidylinositol biosynthetic process | 69/7958 | 131/18723 | 1.19e-02 | 4.35e-02 | 69 |
| GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
| GO:000689810 | Oral cavity | OSCC | receptor-mediated endocytosis | 125/7305 | 244/18723 | 6.56e-05 | 5.32e-04 | 125 |
| GO:00464743 | Oral cavity | OSCC | glycerophospholipid biosynthetic process | 102/7305 | 211/18723 | 3.50e-03 | 1.48e-02 | 102 |
| GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PI4KB | SNV | Missense_Mutation | novel | c.1222N>G | p.Pro408Ala | p.P408A | protein_coding | deleterious(0.02) | possibly_damaging(0.62) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
| PI4KB | SNV | Missense_Mutation | novel | c.1020C>A | p.Phe340Leu | p.F340L | protein_coding | deleterious(0.02) | possibly_damaging(0.798) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PI4KB | SNV | Missense_Mutation | c.2416N>A | p.Asp806Asn | p.D806N | protein_coding | tolerated(0.06) | benign(0.085) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD | ||
| PI4KB | SNV | Missense_Mutation | novel | c.829N>A | p.Leu277Met | p.L277M | protein_coding | tolerated(0.1) | benign(0.205) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| PI4KB | SNV | Missense_Mutation | c.2214N>A | p.Phe738Leu | p.F738L | protein_coding | deleterious(0.01) | possibly_damaging(0.834) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PI4KB | insertion | Nonsense_Mutation | novel | c.1976_1977insGTCTAAACAAAACAAAACAACTAGCTAGCTAG | p.Ala661LysfsTer8 | p.A661Kfs*8 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | |||
| PI4KB | deletion | Frame_Shift_Del | c.233delT | p.Val78GlyfsTer25 | p.V78Gfs*25 | protein_coding | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD | ||||
| PI4KB | deletion | Frame_Shift_Del | novel | c.357delT | p.Val120TrpfsTer24 | p.V120Wfs*24 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| PI4KB | SNV | Missense_Mutation | rs867711084 | c.232G>A | p.Val78Met | p.V78M | protein_coding | tolerated_low_confidence(0.12) | benign(0.397) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| PI4KB | SNV | Missense_Mutation | novel | c.2345G>A | p.Arg782Gln | p.R782Q | protein_coding | tolerated(0.3) | possibly_damaging(0.576) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5298 | PI4KB | KINASE, PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102683 | ||
| 5298 | PI4KB | KINASE, PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 252827496 | ||
| 5298 | PI4KB | KINASE, PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102681 | WORTMANNIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |